Twenty-two women with unexplained heavy menstrual blood loss (average loss for two cycles of >80 ml) were treated with the prostaglandin synthetase inhibitor menfenamic acid during two consecutive menstruations. There was a significant reduction in menstrual blood loss on mefenamic acid therapy, the median loss being 137 ml before treatment and 76 ml while on treatment. Reduction in menstrual loss was achieved in 20 of the 22 patients but varied from a 2% to 78% reduction. The greater the menstrual loss before treatment, the more it was reduced on mefenamic acid therapy. Endometrial concentrations of prostaglandins E2 and F2 alpha in the follicular phase of the cycle were similar whether or not patients had menorrhagia. In the luteal phase, however, 6 of 14 patients with menorrhagia had higher endometrial prostaglandin E2 and F2 alpha concentrations than all 13 controls.

Adolescent↗

PubMedDate not supplied

The measurement of glucocorticoid receptors in human placental cytosol.

Cytosol preparations of human term placenta in Tris-HCl buffer containing dithiothreitol were incubated with [3H]dexamethasone at 4 degrees C. Under these conditions the specific binding of [3H]dexamethasone was low when compared with cytosol preparations of sheep fetal lung or ovine placenta. The inclusion of sodium molybdate in the homogenization buffer and the removal of endogenous steroids by treating the cytosol with charcoal before incubation led to a faster and increased uptake of [3H]dexamethasone by human placenta. Scatchard plot analysis of the data showed that the placenta possesses a single class of high-affinity (Kd = 13 +/- 2 nM) low-capacity (193 +/- 34 fmol/mg protein) binding sites for [3H]dexamethasone. The binding of [3H]dexamethasone was reversible and was not due to plasma contamination. The specificity of the binding sites was confirmed by competition experiments in which the highest displacement of [3H]dexamethasone from the binding sites was caused by natural and synthetic corticosteroids. These findings indicate that the human placenta at term contains specific glucocorticoid receptors in high concentrations.

Binding, Competitive↗

PubMedDate not supplied

Combination coatings unlock medical device potential.

Employing combination coatings, whether multiple coatings on the same surface or different coatings on different parts of the same device offer medical devices a number of benefits. Examples of what can be achieved are reported here.

Catheterization↗

PubMedDate not supplied

Tooth discoloration from tetracyclines.

Explore the source record for details and available documents.

Tetracycline↗